Hyperliquid’s HIP-3 posts $62B, tops perpetuals market
Hyperliquid’s HIP-3 recorded $62 billion in monthly trading volume, lifting the platform to a record share of the global perpetuals market in the most recent reporting period.
Hyperliquid captured a record share of the global perpetuals market after HIP-3, the platform’s flagship perpetuals product, posted $62 billion in trading volume over the most recent month, according to the platform’s reporting period data.
Perpetual contracts are derivatives that let traders hold leveraged positions without a fixed expiry. These contracts account for the bulk of crypto derivatives turnover and are traded continuously across multiple venues worldwide.
Market participants attributed HIP-3’s volume gain to higher liquidity and concentrated order flow on the book, which narrowed bid-ask spreads and supported larger trade sizes. That environment drew both high-frequency trading firms and institutional liquidity providers seeking capacity in major crypto pairs.
Additional platform metrics for the month showed rising open interest and a higher average trade size on HIP-3. Traders who moved capital to the platform cited execution quality and available depth as reasons for redirecting orders.
Hyperliquid’s fee schedule and liquidity incentives were reported to encourage market makers to post continuous bids and offers, contributing to deeper order books and more consistent fills for larger orders.
The platform’s monthly figures add to data on where derivatives volume is concentrated among trading venues. Further monthly reports will indicate whether HIP-3 sustains its increased share or if volumes redistribute across competing platforms.
The content on The Coinomist is for informational purposes only and should not be interpreted as financial advice. While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, or reliability of any content. Neither we accept liability for any errors or omissions in the information provided or for any financial losses incurred as a result of relying on this information. Actions based on this content are at your own risk. Always do your own research and consult a professional. See our Terms, Privacy Policy, and Disclaimers for more details.








